Abstract:Aurora kinases A and B are critical regulators of cell division and cytokinesis. Abnormal expression of Aurora kinases A and B causes chromosomal instability and disrupts several tumor suppressor and oncoprotein-controlled pathways. As a result, there has been a spike in interest in developing inhibitors against these kinases as anticancer treatments. This paper addresses the discovery, anticancer evaluation and druggability study of new pyrazole-4-carboxamide analogues as kinases inhibitors. Among the compounds, 6k demonstrated the highest cytotoxicity against Hela and HepG2 cells, with IC 50 of 0.43 μM and 0.67 μM, respectively. It selectively inhibited Aurora kinases A and B, with IC 50 values of 16.3 nM and 20.2 nM, respectively, in comparison to other kinases. Molecular investigations revealed that 6k induced the inhibition of phosphorylated Thr288 (Aurora kinase A) and phosphorylated Histone H3 (Aurora kinase B), confirming its mechanism of action. Beside, compound 6k arrested the cell cycle at the G2/M phase by modulating cyclinB1 and cdc2 protein levels and increasing the Sub-G1 cell population. It also significantly increased polyploidization (>8N) and abnormal mitosis, likely due to Aurora kinase inhibition. Furthermore, 6k boosted apoptosis through the intrinsic route, with elevated levels of p53, Bak, Bax, cleaved caspase-3, and cleaved PARP. Moreover, docking and MD simulations validated kinase inhibition-induced anticancer effects. Additionally, 6k satisfied drug-likeness parameters and remained stable in the in vitro metabolism. These findings indicate that 6k warrants further in vivo pharmacokinetic and pharmacodynamics investigations.

Synthesis and Biological Evaluation of Aurora Kinases Inhibitors Based on N-trisubstituted Pyrimidine Scaffold

Design, Synthesis and Bioevaluation of N-trisubstituted Pyrimidine Derivatives As Potent Aurora A Kinase Inhibitors

Synthesis and biological evaluation of nitroxide labeled pyrimidines as Aurora kinase inhibitors.

Synthesis and Biological Evaluation of 2,4-Diaminopyrimidines As Selective Aurora A Kinase Inhibitors.

Identification of novel inhibitors of Aurora A with a 3-(pyrrolopyridin-2-yl)indazole scaffold.

Synthesis, biological evaluation and molecular modeling study of 2-amino-3,5-disubstituted-pyrazines as Aurora kinases inhibitors

Discovery of Novel 2,4-Disubstituted Pyrimidines As Aurora Kinase Inhibitors.

Structure-based Drug Design: Synthesis and Biological Evaluation of Quinazolin-4-amine Derivatives As Selective Aurora A Kinase Inhibitors.

Synthesis, biological evaluation, and molecular docking studies of N,1,3-triphenyl-1H-pyrazole-4-carboxamide derivatives as anticancer agents.

Synthesis and Biological Evaluation of 2,4-Disubstituted Phthalazinones As Aurora Kinase Inhibitors.

Synthesis and Quantum Chemical Studies of New 4-Aminoquinazoline Derivatives As Aurora A/B Kinase Inhibitors

Pyrazolo[4,3-b]pyrimido[4,5-e][1,4]diazepine Derivatives As New Multi-Targeted Inhibitors of Aurora A/B and KDR.

The Synthesis and Anti-Tumour Properties of Novel 4-Substituted Phthalazinones As Aurora B Kinase Inhibitors.

Discovery of 4-Aminoquinazoline—urea Derivatives As Aurora Kinase Inhibitors with Antiproliferative Activity

Design, synthesis, biological activity evaluation of 3-(4-phenyl-1H-imidazol-2-yl)-1H-pyrazole derivatives as potent JAK 2/3 and aurora A/B kinases multi-targeted inhibitors

Design, Synthesis, Biological Evaluation of 6-(2-amino-1h-benzo[d]imidazole-6-yl)quinazolin-4(3h)-one Derivatives As Novel Anticancer Agents with Aurora Kinase Inhibition.

Design, synthesis and biological evaluation of 2-aminopyrimidine derivatives as potent FLT3 inhibitors.

Design, Synthesis, Quantum Chemical Studies and Biological Activity Evaluation of Pyrazole-Benzimidazole Derivatives As Potent Aurora A/B Kinase Inhibitors.

Design, synthesis, and biological evaluation of 6-(imidazo[1,2-a] pyridin-6-yl) quinazolin-4(3H)-one derivatives as potent anticancer agents by dual targeting Aurora kinase and ROR1

Design, Synthesis and Bioevaluation of Dihydropyrazolo[3,4-B]pyridine and Benzo[4,5]imidazo[1,2-A]pyrimidine Compounds As Dual KSP and Aurora-A Kinase Inhibitors for Anti-Cancer Agents.

Discovery of new pyrazole-4-carboxamide analogues as potential anticancer agents targeting dual Aurora kinase A and B